Randomized trial · people
Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with HIV and extra belly fat on ART, tesamorelin shrank deep belly fat compared with placebo, and the loss held through 52 weeks in those who kept taking it.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 806
- Published
- 2010
- Journal
- J Clin Endocrinol Metab
What they tested
The team tested whether tesamorelin shrinks visceral fat (deep fat around the organs) in people with HIV on antiretroviral therapy (ART, HIV medicines) who carry extra belly fat.
How the study was done
A pooled analysis of two randomized, double-blind, placebo-controlled phase 3 trials in 806 people with HIV on ART, given a daily under-the-skin shot of tesamorelin 2 mg (543 people) or placebo, a dummy shot (263 people), for 26 weeks. A 26-week extension followed: some on tesamorelin were randomized again to stay on it (246) or switch to placebo (135), and those on placebo switched to tesamorelin (197).

What they found
At 26 weeks, visceral fat on CT scan fell by 24 cm² with tesamorelin and rose by 2 cm² with placebo, a treatment effect of -15.4%. Fat just under the skin of the belly did not change significantly, while triglycerides dropped by 37 mg/dl versus a 6 mg/dl rise on placebo, and IGF-I rose by 108 ng/ml versus a 7 ng/ml drop. Body image and patient and physician ratings of belly shape also improved. In people who stayed on tesamorelin for 52 weeks, visceral fat was down 35 cm² (17.5%) and waist size down 3.4 cm from the start, most people tolerated the drug, and glucose measures showed no meaningful differences between groups.
What it doesn’t show
The placebo comparison lasted only 26 weeks; the 52-week results compare one group with its own starting point, not with placebo. Everyone studied had HIV and was on ART, so it does not show effects in other people.
The paper
Falutz et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.